Pharma Contract Sales Market Report 2025-2035: CRO-CSO Integration Enhances Commercialisation Models [Yahoo! Finance]
Scienture Holdings, Inc. (SCNX)
Company Research
Source: Yahoo! Finance
U.S. trade tariffs create opportunities for CSOs to provide cost-effective, flexible solutions. Key prospects lie in regional expansion, strategic partnerships, and adaptive sales models. Dublin, Jan. 05, 2026 (GLOBE NEWSWIRE) -- The "Pharma Contract Sales Market Report 2025-2035" has been added to ResearchAndMarkets.com's offering. The global Pharma Contract Sales Market is projected to exceed US$13.0 billion in value by 2025, with continued robust growth expected through 2035. This trajectory offers lucrative opportunities for organizations within this sector. The report identifies key players and their capabilities, aiding firms aiming to discover new revenue avenues and a deeper understanding of market dynamics. Companies expanding into diverse industries or new regions will find this report invaluable. CRO-CSO Integration Enhances Commercialisation Models Pharmaceutical firms are focusing on integrated service providers that streamline processes from clinical trials to
Show less
Read more
Impact Snapshot
Event Time:
SCNX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SCNX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SCNX alerts
High impacting Scienture Holdings, Inc. news events
Weekly update
A roundup of the hottest topics
SCNX
News
- SCIENTURE Announces Issuance of Orange Book-Listable Patent Covering REZENOPY™, the Highest Dosage Naloxone HCl Nasal Spray Approved by the FDA for Life-Saving Opioid Overdose Emergency TreatmentGlobeNewswire
- SCIENTURE Provides Update on the Commercial Launch of REZENOPY®, the Highest Strength Naloxone HCl Life-Saving Opioid Overdose Emergency Treatment Approved by the FDA [Yahoo! Finance]Yahoo! Finance
- SCIENTURE Provides Update on the Commercial Launch of REZENOPY®, the Highest Strength Naloxone HCl Life-Saving Opioid Overdose Emergency Treatment Approved by the FDAGlobeNewswire
- Scienture, BlinkRx announce strategic collaboration to expand access to Arbli [Yahoo! Finance]Yahoo! Finance
- SCIENTURE and BlinkRx Announce Strategic Collaboration to Expand Patient Access to Arbli™, the First FDA-Approved Ready-to-Use Oral Suspension of Losartan PotassiumGlobeNewswire
SCNX
Sec Filings
- 11/18/25 - Form 8-K
- 11/14/25 - Form 8-K
- 11/14/25 - Form SCHEDULE
- SCNX's page on the SEC website